BR100 Increased By (0.02%)
BR30 Increased By (0.06%)
KSE100 Decreased By (-0%)
KSE30 Increased By (0.05%)
BECO 5.52 Decreased By ▼ -0.02 (-0.36%)
BML 56.70 Decreased By ▼ -0.39 (-0.68%)
BOP 35.20 Decreased By ▼ -0.01 (-0.03%)
CNERGY 8.15 Decreased By ▼ -0.05 (-0.61%)
DCL 11.61 Decreased By ▼ -0.03 (-0.26%)
FCCL 56.61 Increased By ▲ 0.12 (0.21%)
FCSC 5.38 Increased By ▲ 0.06 (1.13%)
FFL 17.95 Decreased By ▼ -0.11 (-0.61%)
FNEL 1.29 No Change ▼ 0.00 (0%)
HUMNL 11.10 Decreased By ▼ -0.09 (-0.8%)
KEL 8.39 Increased By ▲ 0.19 (2.32%)
KOSM 6.63 Decreased By ▼ -0.04 (-0.6%)
MLCF 101.06 Increased By ▲ 0.30 (0.3%)
NBP 202.44 Decreased By ▼ -0.56 (-0.28%)
PACE 11.42 Decreased By ▼ -0.07 (-0.61%)
PAEL 43.32 Increased By ▲ 0.24 (0.56%)
PIAHCLA 27.24 Increased By ▲ 0.24 (0.89%)
PIBTL 17.82 Decreased By ▼ -0.02 (-0.11%)
PPL 244.79 Increased By ▲ 2.16 (0.89%)
PRL 35.71 Decreased By ▼ -0.16 (-0.45%)
PTC 65.45 Decreased By ▼ -0.40 (-0.61%)
SEARL 93.55 Decreased By ▼ -0.03 (-0.03%)
SSGC 32.98 Increased By ▲ 0.75 (2.33%)
TELE 9.04 Decreased By ▼ -0.07 (-0.77%)
THCCL 66.80 Increased By ▲ 0.31 (0.47%)
TPLP 10.85 Decreased By ▼ -0.10 (-0.91%)
TREET 25.48 Decreased By ▼ -0.24 (-0.93%)
TRG 65.90 Decreased By ▼ -0.05 (-0.08%)
WAVES 11.13 Decreased By ▼ -0.03 (-0.27%)
WTL 1.27 Increased By ▲ 0.01 (0.79%)
Business & Finance

European Commission signs third contract with BioNTech-Pfizer for 1.8bn vaccine doses

  • The contract reserves the doses on behalf of all European Union member states, between end 2021 to 2023, the statement added. The contract requires that the vaccine production is based in the EU and that essential components are sourced from the EU.
Published May 20, 2021 Updated May 20, 2021 06:38pm
By

The European Commission said on Thursday that it signed a third contract with pharmaceutical companies BioNTech SE and Pfizer Inc for an additional 1.8 billion doses of the coronavirus vaccine.

The contract reserves the doses on behalf of all European Union member states, between end 2021 to 2023, the statement added. The contract requires that the vaccine production is based in the EU and that essential components are sourced from the EU.

Comments

Comments are closed for this article.